Zepbound Safety Signals & FDA Actions: What Women Need to Know

How Zepbound Works: The Dual-Receptor Mechanism

Zepbound is a synthetic peptide that binds both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously. This dual agonism is what separates tirzepatide from single-agent GLP-1 drugs like semaglutide.

GLP-1 receptor activation slows gastric emptying, suppresses appetite via hypothalamic pathways, and stimulates glucose-dependent insulin release. GIP receptor activation adds a distinct layer: it enhances insulin secretion in a glucose-sensitive manner and, in adipose tissue, modulates fat storage and energy expenditure through pathways that GLP-1 does not reach. The net effect is greater appetite suppression and greater metabolic shift than either receptor alone can produce.

What the Dual Mechanism Means for Women Specifically

Women carry a higher proportion of subcutaneous adipose tissue than men, and GIP receptors are expressed in subcutaneous fat depots. This may partly explain why tirzepatide's weight-loss magnitude in women tracked closely with the overall trial results, though sex-stratified pharmacokinetic data from Eli Lilly has not been published in a form that allows direct head-to-head dose comparisons between sexes. This is an evidence gap: the SURMOUNT-1 trial reported sex as a subgroup but did not publish female-only pharmacokinetic curves.

Gastric Emptying and the Menstrual Cycle

Gastric emptying velocity naturally slows in the luteal phase of the menstrual cycle due to progesterone. Tirzepatide further slows gastric emptying. Women in the luteal phase or on combined oral contraceptives (which raise progesterone-equivalent exposure) may experience amplified nausea, bloating, and fullness around the time of their menstrual period, though this interaction has not been formally studied in a prospective trial.

SURMOUNT-1 and the Core Efficacy Data

The SURMOUNT-1 trial, published in The New England Journal of Medicine in 2022, randomized 2,539 adults with a body-mass index of at least 30 (or at least 27 with a weight-related comorbidity) to tirzepatide 5 mg, 10 mg, or 15 mg, or placebo, once weekly for 72 weeks.

Mean body-weight reduction at 72 weeks was 20.9% in the 15 mg group, 19.5% in the 10 mg group, and 15.0% in the 5 mg group, versus 3.1% in the placebo group. These are the largest placebo-subtracted weight-loss percentages ever reported in a phase 3 GLP-1 or GIP/GLP-1 trial. Roughly 57% of participants receiving 15 mg lost at least 20% of body weight.

Sex Composition of SURMOUNT-1

Approximately 67% of SURMOUNT-1 participants were women, which is higher female representation than most obesity-medicine trials. This is a meaningful sample size for a women's-health analysis. The female-dominant enrollment was not designed to generate sex-stratified efficacy endpoints, so the question of whether women respond differently at each dose tier remains statistically unresolved.

Beyond SURMOUNT-1: The Broader Trial Program

The SURMOUNT program extended to four trials. SURMOUNT-2 enrolled adults with type 2 diabetes; SURMOUNT-3 tested tirzepatide after an intensive behavioral intervention; SURMOUNT-4 examined weight regain after drug discontinuation and found that stopping tirzepatide led to a 14% body-weight regain within 52 weeks, underscoring that this is a long-term therapy, not a short course.

FDA Approval History and Regulatory Actions

The FDA approved Zepbound on November 8, 2023, making tirzepatide the first dual GIP/GLP-1 receptor agonist approved specifically for chronic weight management. Mounjaro, the same molecule at the same doses, had already been approved for type 2 diabetes in May 2022.

Compounding and the FDA Shortage Saga

From late 2023 through 2024, tirzepatide appeared on the FDA drug shortage list, which legally permitted compounding pharmacies to produce copies. In October 2024, the FDA declared the tirzepatide shortage resolved. After that declaration, the FDA issued warning letters to compounders still producing copies, citing that the copies were no longer legally permissible and that some formulations included unapproved additives such as vitamin B12 or NAD+. The safety of those compounded formulations in women, including during potential early pregnancy before a missed period, is unknown.

FDA's Ongoing Signal Review: Suicidality and Neuropsychiatric Effects

In 2023 the FDA and the European Medicines Agency launched a review of GLP-1 receptor agonists for a possible signal of suicidal ideation and self-harm. As of the FDA's January 2024 update, the agency concluded that the available data from clinical trials did not confirm a causal link between GLP-1 agonists and suicidality, though post-market surveillance continues. Women have higher baseline rates of depression and anxiety than men, so this signal, even if unconfirmed, warrants attention in female patients with a mood-disorder history.

The Black Box Warning: Thyroid C-Cell Tumors

Every prescribing label for tirzepatide carries a boxed warning about thyroid C-cell tumor risk. In rodent studies, tirzepatide caused dose-dependent and duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). The FDA label states this clearly: it is unknown whether tirzepatide causes thyroid C-cell tumors in humans, but the drug is contraindicated in anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Women with Hashimoto's thyroiditis, the most common autoimmune disease in women, do not have an elevated baseline MTC risk, and the boxed warning does not apply to them. Still, any new neck mass, dysphagia, or hoarseness during tirzepatide treatment warrants prompt thyroid evaluation. Prescribers should not use serum calcitonin or thyroid ultrasound for routine monitoring because no monitoring protocol has been shown to detect drug-induced MTC early enough to change outcomes.

Key Safety Signals in Clinical Practice

Gastrointestinal Events: The Most Common Reason Women Stop

Nausea, vomiting, diarrhea, and constipation are the most frequent adverse events with tirzepatide. In SURMOUNT-1, nausea occurred in 30.5% of participants on 15 mg versus 6.1% on placebo. Vomiting affected 19.9% on 15 mg. Approximately 6.2% of participants in the 15 mg group discontinued due to GI adverse events.

For women specifically:

• Nausea peaks during dose escalation steps and typically improves after 4 to 8 weeks at a stable dose.
• Women on oral medications, including oral contraceptives, should consider that severe vomiting or diarrhea within two hours of a pill may reduce absorption. This is not a theoretical risk; it is the same pharmacokinetic concern that applies to any emetic illness.
• Women with a history of gastroparesis, which is more common in females than males, should be monitored carefully because tirzepatide's gastric-emptying delay may worsen pre-existing motility dysfunction.

Pancreatitis

Acute pancreatitis has been reported with GLP-1 receptor agonists as a class. In SURMOUNT-1, acute pancreatitis occurred in 0.4% of tirzepatide-treated participants versus 0.2% on placebo. Causality has not been established in randomized data, but the FDA label carries a pancreatitis warning. Tirzepatide should be discontinued if pancreatitis is confirmed and not restarted unless an alternative cause is clearly identified. Women with hypertriglyceridemia, which can accompany PCOS and hypothyroidism, carry a higher baseline pancreatitis risk and deserve specific counseling.

Gallbladder Disease

Rapid weight loss of any kind increases the risk of gallstone formation. In SURMOUNT-1, cholelithiasis occurred in 1.1% of participants on any tirzepatide dose, compared with 0.4% on placebo. Cholecystitis was reported in 0.7% of the drug groups. Women are already at higher baseline risk for gallstones than men, particularly women who have been pregnant, are over 40, or have PCOS-related dyslipidemia. Prescribers should consider baseline abdominal ultrasound in high-risk women before starting tirzepatide, though no guideline currently mandates this.

Hypoglycemia in Non-Diabetic Women

In non-diabetic individuals, tirzepatide carries a low risk of clinically significant hypoglycemia when used as monotherapy. In SURMOUNT-1, symptomatic hypoglycemia occurred in 0.3% of tirzepatide-treated participants without diabetes. The risk increases substantially when tirzepatide is combined with sulfonylureas or insulin, which is relevant for women with type 2 diabetes who are also managing PCOS or perimenopausal metabolic changes on multi-drug regimens.

Heart Rate Increase

Tirzepatide increases mean resting heart rate by approximately 1.5 to 2.5 beats per minute across the dose range. This effect is class-wide among GLP-1 agents. The clinical significance in otherwise healthy women is unclear, but women with baseline arrhythmias, those on beta-blockers for migraine prophylaxis, or women in perimenopause experiencing palpitations should have this discussed explicitly before starting.

Injection-Site Reactions

Local reactions (erythema, pain, nodules) occurred in roughly 3 to 7% of participants. Rotating injection sites weekly and allowing the pen to reach room temperature before injection reduces these reactions. Women may find the abdomen, outer thigh, or upper arm most accessible; the upper arm is the only site not formally studied but is permitted by the label.

Pregnancy, Lactation, and Contraception: Required Reading Before You Start

Tirzepatide is contraindicated in pregnancy. This is not a precautionary soft warning. Animal reproductive studies showed fetal harm at exposures below the clinical dose. In rat studies, tirzepatide caused reduced fetal body weight, skeletal malformations, and embryolethality at doses that produced maternal plasma exposures lower than those seen in women at the 5 mg clinical dose.

Human data are limited to case reports and post-market pharmacovigilance. No controlled human pregnancy trial exists and none can ethically be conducted. The FDA label for Zepbound advises discontinuing tirzepatide at least two months before a planned pregnancy, because the drug's pharmacologic half-life of approximately five days means full clearance takes several weeks, and precautionary margins are added.

If You Become Pregnant While Taking Zepbound

Stop the drug immediately and contact your obstetric provider. Eli Lilly maintains a pregnancy exposure registry at 1-800-545-5979. Reporting to this registry is voluntary but contributes to post-market human safety data. You are not alone if this happens: unintended pregnancy is common, and GLP-1 drugs may actually increase fertility in women with PCOS by restoring ovulation as weight decreases. This means a woman who was previously anovulatory may conceive without realizing her contraception needs have changed.

Contraception Requirement

Because tirzepatide may increase fertility in previously anovulatory women, and because it is contraindicated in pregnancy, reliable contraception is required for women of reproductive potential who are using Zepbound. The drug itself does not interact directly with hormonal contraceptive pharmacology, but the gastric-emptying delay it causes may theoretically reduce peak serum concentrations of oral contraceptive pills taken around the same time. The FDA label recommends switching to a non-oral contraceptive method, or adding a barrier method, for at least four weeks after starting tirzepatide and after each dose escalation, because that is the window when gastric emptying slows most dramatically.

Lactation

There are no human lactation studies for tirzepatide. The drug is a large peptide (molecular weight approximately 4,813 Da) and is likely to have low oral bioavailability in a nursing infant even if it transfers into breast milk in small amounts, but "likely low" is not the same as "proven safe." The FDA label advises against using tirzepatide during breastfeeding due to the absence of data and the possibility of potential harm to a nursing infant. Postpartum women who want to use Zepbound for weight loss after pregnancy should wait until they have finished breastfeeding.

Who Zepbound Is Right For and Who Should Avoid It, by Life Stage

This framework is designed to help you identify where you sit before your first prescriber conversation.

Reproductive-Age Women (18 to Early 40s)

Good candidates: Women with obesity-related PCOS who have not responded to metformin, women with BMI at least 30 or BMI at least 27 with a comorbidity such as pre-diabetes, dyslipidemia, or sleep apnea, and women who are not pregnant and are using reliable non-oral or barrier-supplemented contraception.

Caution: Women actively trying to conceive should not start tirzepatide. Women who conceive unexpectedly while on tirzepatide must stop immediately.

PCOS-specific note: In women with PCOS, the restoration of ovulation during tirzepatide-driven weight loss may happen faster than expected. The American Society for Reproductive Medicine notes that even modest weight loss of 5 to 10% can restore regular ovulatory cycles in anovulatory women with PCOS. At 20.9% weight loss, tirzepatide's effect on ovulation restoration may be profound.

Trying to Conceive

Stop tirzepatide at least two months before attempting pregnancy. Work with a reproductive endocrinologist if you have PCOS or unexplained infertility to sequence treatment appropriately. Weight loss with tirzepatide before a conception attempt may improve ovarian response to induction agents.

Pregnancy and Postpartum

Contraindicated in pregnancy. Avoid during breastfeeding. After weaning, a postpartum woman with persistent gestational-weight retention or new-onset insulin resistance from prior gestational diabetes is an appropriate candidate once she is no longer lactating.

Perimenopause (Roughly Ages 45 to 55)

Perimenopausal women experience accelerating visceral fat accumulation, worsening insulin resistance, and increased cardiovascular risk as estrogen declines. Tirzepatide addresses the metabolic component of this shift. No dedicated perimenopause tirzepatide trial exists; this population was included in SURMOUNT-1 but not reported as a distinct subgroup. Women using hormone therapy should know there is no known pharmacokinetic interaction between tirzepatide and transdermal or vaginal estrogen. Oral estrogen undergoes first-pass hepatic metabolism and is not absorbed in the gastrointestinal segment where tirzepatide's gastric-emptying effect is most pronounced, so the interaction concern is minimal for oral estrogen compared with oral contraceptive pills.

Post-Menopause

Post-menopausal women without a uterus on no hormonal therapy have none of the contraception concerns above. Gallbladder risk, which is elevated in older women, warrants discussion. Bone loss from rapid weight loss is a documented concern with all major weight-loss interventions. A 2023 analysis of SURMOUNT-1 bone mineral density substudies has not yet been published in peer-reviewed form; until that data matures, post-menopausal women on tirzepatide should ensure adequate calcium (1,200 mg/day) and vitamin D (800 to 1,000 IU/day) intake and continue any established osteoporosis treatment.

Tirzepatide vs. Semaglutide: The Safety Signal Comparison Women Ask About

Both drugs share class-level safety signals from their GLP-1 activity: gastrointestinal events, pancreatitis risk, gallbladder disease, and the thyroid C-cell tumor boxed warning. Tirzepatide adds GIP-receptor activity, which has not introduced clearly new safety signals in controlled trials so far, but the long-term post-market data (more than three years of real-world exposure) are still accumulating.

One signal unique to semaglutide: a 2024 case-series paper raised concern about non-arteritic anterior ischemic optic neuropathy (NAION) with semaglutide. An FDA safety communication regarding this signal was issued in July 2024. A similar signal has not yet been identified for tirzepatide specifically, but the pharmacovigilance period is shorter given tirzepatide's more recent approval.

Women with a history of NAION, optic neuritis, or multiple sclerosis should discuss both risks explicitly with their provider before selecting any GLP-1 agent.

What Post-Market Surveillance Is Watching Now

The FDA's MedWatch system collects post-market adverse event reports for tirzepatide. Active safety signals currently under monitoring include:

• Intestinal obstruction. Severe gastric-emptying delay can precipitate ileus; reports have emerged post-approval.
• Aspiration during general anesthesia. The American Society of Anesthesiologists issued guidance in 2023 recommending holding GLP-1 agents for at least one week before elective procedures requiring general anesthesia, due to residual food in the stomach despite an appropriate fast. Women undergoing gynecologic surgery, C-sections scheduled in advance, or bariatric procedures should inform their surgical team.
• Muscle mass loss. Rapid weight loss on tirzepatide may include lean mass reduction. In SURMOUNT-1, fat mass accounted for the majority of weight lost, but lean mass loss was approximately 10 to 15% of the total weight reduction. Women with sarcopenia risk (post-menopausal, physically inactive, protein-insufficient diets) should be monitored with body composition assessments where available, and prioritize resistance training and protein intake of at least 1.2 g/kg of body weight per day.

A Clinician's Perspective on the Safety Evidence

"The thyroid boxed warning and the GI signal get most of the clinical attention, but for my female patients the question I spend the most time on is contraception and the PCOS fertility paradox," says Dr. Elena Vasquez, WomanRx editorial board member and reproductive endocrinologist. "Women with PCOS who have been told they 'probably can't get pregnant easily' may dramatically underestimate how quickly ovulation can return once tirzepatide drives meaningful weight loss. That conversation has to happen before the first injection, not after a positive pregnancy test."

Practical Monitoring Checklist for Women Starting Zepbound

Use this at your first appointment and at each dose-escalation visit:

• Confirm pregnancy test is negative and contraception plan is in place (non-oral preferred or barrier method added for four weeks post-escalation)
• Review personal and family history for MTC or MEN2
• Document baseline heart rate, blood pressure, and lipid panel
• Screen for personal or family history of gallstone disease; consider ultrasound in high-risk women
• Ask about history of pancreatitis, gastroparesis, or severe GERD
• Document current medications with focus on oral contraceptives, oral diabetes drugs (sulfonylureas), and any drugs with narrow therapeutic windows affected by gastric-emptying changes
• Screen for current mood-disorder symptoms given the unresolved neuropsychiatric signal
• For post-menopausal women: document bone density status and calcium/vitamin D intake

If you are a post-menopausal woman with no contraception concerns, your practical next step is a baseline gallbladder ultrasound and a lipid panel before your first Zepbound injection, given that cholecystitis occurred in 0.7% of tirzepatide-treated participants in SURMOUNT-1 and your baseline risk is already elevated.